Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone Liposome Combinations in De Novo AML
NCT05941585Completed
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Aug 2023
- Primary completion
- Jan 2025
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in acute myeloid leukemia (AML) (3 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Treatment-Emergent Adverse Events at 1 month. Started Aug 2023; status: completed.
02
Drugs
mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05941585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05941585.